Ondrey Aaron reported grant involving 270,000 derivative units of Syndax Pharmaceuticals Inc at $9.55 for $2.58M on Nov 9, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Chief Financial Officer
Chief Financial Officer
Filed Nov 12, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$2,578,500Shares × reported price
Shares traded
270,000Stock Option (Right to buy)
Price per share
$9.55Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
0Direct
Trade date
Nov 9, 2026Grant
Filed
Nov 12, 2026, 4:05 PM ET3-day reporting delay
Accession
0001193125-26-458304Code A · Transaction 398693
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

SNDX price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
SNDX · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 19, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago 0%1w ago 0%1d ago 0%
Returns since7d30d90d180d1y

Footnotes in full

F1: Twenty-five percent (25%) of the total number of shares will vest on the one (1) year anniversary of the Vesting Commencement Date and one forty-eighth (1/48th) of the shares of Common Stock subject to the Option shall vest monthly thereafter during the recipient's continued service as an employee, consultant, director or officer of the Company over the following thirty-six (36) months, until all of the shares subject to the Option are fully vested.